A Phase 2 interventional study of LDE225 in Basal Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Completed at 62 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 11th largest by enrollment of the 139 interventional ones that give a count, is one of 8 that started in 2011, is one of 46 in phase 2, and was the 54th registered.
389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.
Browse Carcinoma, Basal Cell studies →23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
University of Rochester · Sites in United States
University of Rochester · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 58 · Phase 3 7 · Phase 4 5
First in 1977; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is above the median of 50 across 272 interventional studies indexed under Carcinoma, Basal Cell.
Median enrollment 40 across the 139 interventional studies, 80 across the 26 observational. Of the 119 that completed or were terminated, 48 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 171 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 8 studies filed under Carcinoma, Basal Cell — fewer than ten, so there is no comparison to draw.
19 of the studies in Carcinoma, Basal Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608511University of Wisconsin, MadisonLiquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | 2026-12 |
| NCT06623201Nathalie ZeitouniBlue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas | 2026-12-01 |
| NCT04616248University of Southern CaliforniaIn Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | 2027-01-09 |
| NCT06384924Tiezhi ZhangRaman Spectroscopy and Skin Cancer | 2027-02-13 |
| NCT05294120Memorial Sloan Kettering Cancer CenterA Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma | 2027-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
Drug: LDE225
The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
Drug: LDE225
LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
Also known as: Sonidegib
Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)
ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 6 months after starting LDE225 treatment.Treatment with sonidegib was considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 6 months
Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)
ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 6 months after starting LDE225 treatment.Treatment with sonidegib was to be considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 6 months
Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. Progressive disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Time frame: 42 months
Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)
Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Median DoR for patients with laBCC was non-estimable for both treatment arms. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 42 months
Complete Response Rate (CRR) Per Central Review (pEAS)
Rate of complete response is the percentage of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR was determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown" were treated as non responders. Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 42 months
Complete Response Rate (CRR) Per Central Review (FAS)
Rate of complete response is the proportion of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR will be determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown" will be treated as non responders
Time frame: 6 months
Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.
Time frame: 42 months
Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)
Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.
Time frame: 42 months
Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 42 months
Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)
Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 42 months
Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)
ORR is the percentage of patient's objective response (ORR) by 42 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 42 months after starting LDE225 treatment. Treatment with sonidegib was considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 42 months
Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)
ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 42 months after starting LDE225 treatment.Treatment with sonidegib was to be considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 42 months
Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. Progressive disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Time frame: 42 months
Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)
Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 42 months
Progression-free Survival (PFS) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.
Time frame: 42 months
Time to Tumor Response (TTR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS)
Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
Time frame: 42 months
Plasma Concentration of Sonidegib (LDE225)
Blood PK samples were collected either by direct venipuncture or an indwelling cannula inserted in a forearm vein for the determination of trough (Cmin) plasma concentrations of sonidegib and its main circulating metabolite, LGE899, from all patients who enrolled in the study. Blood was collected in Weeks 1, 3, 5, 9 (pre-dose), and subsequently pre-dose every 4 weeks up to Week 21, and every 12 weeks thereafter up to week 69.
Time frame: Weeks 1, 3, 5, 9, 13, 17, 21, 33, 45, 57, 69
Overall Survival (OS)
OS is defined as the time from date of randomization to date of death due to any cause or the last date that a patient was known to be alive (censored observation) as of the data cut-off.
Time frame: 42 months
Randomization was stratified across the two treatment arms according to the stage of disease (laBCC or mBCC), histological subtype (non-aggressive or aggressive for laBCC patients) and the regions (Australia, Europe, and North America).
| Milestone | LDE225 (Sonidegib) 200 mg | LDE225 (Sonidegib) 800 mg |
|---|---|---|
| Started | 79 | 151 |
| Untreated | 0 | 1 |
| Patients cont. to next phase of trial | 52 | 89 |
| Survival follow-up | 33 | 49 |
| Post-treatment follow-up | 19 | 40 |
| Completed | 0 | 0 |
| Not completed | 79 | 151 |
| Withdrew: Adverse event | 23 | 57 |
| Withdrew: Patient/guardian decision | 11 | 35 |
| Withdrew: Physician decision | 10 | 14 |
| Withdrew: Death | 1 | 5 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Non-compliance with study treatment | 0 | 5 |
| Withdrew: Study terminated by sponsor | 1 | 3 |
| Withdrew: Progressive disease | 31 | 26 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Untreated | 0 | 1 |
ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 6 months after starting LDE225 treatment.Treatment with sonidegib was considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Percentage of participants | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS) | 42.9 (27.7 to 59.0) | 37.6 (27.8 to 48.3) | 15.4 (1.9 to 45.4) | 17.4 (5.0 to 38.8) |
ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 6 months after starting LDE225 treatment.Treatment with sonidegib was to be considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Percentage of participants | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS) | 47.0 (34.6 to 59.7) | 35.2 (26.9 to 44.1) | 15.4 (1.9 to 45.4) | 17.4 (5.0 to 38.8) |
Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. Progressive disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS) | 12.9 (NA to NA) | 23.7 (10.8 to 29.6) | 24.0 (NA to NA) | NA (NA to NA) |
Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Median DoR for patients with laBCC was non-estimable for both treatment arms. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Duration of Response (DoR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS) | 26.1 (NA to NA) | 23.3 (12.2 to 29.6) | 24.0 (NA to NA) | NA (NA to NA) |
Rate of complete response is the percentage of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR was determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown" were treated as non responders. Complete Response (CR): Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Percentage of participants | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Complete Response Rate (CRR) Per Central Review (pEAS) | 4.8 (0.6 to 16.2) | 2.2 (0.3 to 7.6) | 0.0 (0.0 to 24.7) | 0.0 (0.0 to 14.8) |
Rate of complete response is the proportion of patients with best overall response of complete response (CR) after starting LDE225 treatment. The rate of CR will be determined according to mRECIST for laBCC and RECIST 1.1 for mBCC. Patients with best overall response of 'Unknown" will be treated as non responders
| Percentage of participants | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Complete Response Rate (CRR) Per Central Review (FAS) | 3.0 (0.4 to 10.5) | 0.0 (0.0 to 2.8) | 0.0 (0.0 to 24.7) | 0.0 (0.0 to 14.8) |
Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS) | 19.0 (NA to NA) | 19.4 (13.8 to 30.5) | 13.1 (5.6 to 33.1) | 11.1 (7.3 to 16.6) |
Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Progression-free Survival (PFS) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS) | 22.1 (NA to NA) | 24.9 (19.2 to 33.4) | 13.1 (5.6 to 33.1) | 11.1 (7.3 to 16.6) |
Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS) | 4.0 (3.7 to 5.6) | 3.7 (2.0 to 5.5) | 9.2 (NA to NA) | 1.0 (1.0 to 2.1) |
Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Time to Tumor Response (TTR) Per Central Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS) | 4.0 (3.7 to 5.6) | 3.7 (2.0 to 5.5) | 9.2 (NA to NA) | 1.0 (1.0 to 2.1) |
ORR is the percentage of patient's objective response (ORR) by 42 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 42 months after starting LDE225 treatment. Treatment with sonidegib was considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Percentage of participants | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS) | 71.4 (55.4 to 84.3) | 61.3 (50.6 to 71.2) | 23.1 (5.0 to 53.8) | 34.8 (16.4 to 57.3) |
ORR is the percentage of patient's objective response (ORR) by 6 months after starting LDE225 treatment. A responder was defined as a subject with confirmed partial response (PR) or confirmed complete response (CR) 42 months after starting LDE225 treatment.Treatment with sonidegib was to be considered sufficiently efficacious if the observed ORR on any treatment arm at the end of the study was 30% or higher. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Percentage of participants | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Objective Response Rate (ORR) Based on Site Investigator Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS) | 71.2 (58.7 to 81.7) | 58.6 (49.6 to 67.2) | 23.1 (5.0 to 53.8) | 34.8 (16.4 to 57.3) |
Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. Progressive disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS) | 18.2 (12.9 to 23.0) | 26.0 (15.7 to 47.3) | 18.1 (17.7 to 18.4) | 10.2 (NA to NA) |
Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS) | 15.7 (12.0 to 20.2) | 26.0 (18.3 to 47.3) | 18.1 (17.7 to 18.4) | 10.2 (NA to NA) |
Progression-free survival (PFS) is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Progression-free Survival (PFS) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS) | 20.1 (14.8 to 23.8) | 28.0 (19.4 to 49.8) | 13.1 (9.2 to 19.4) | 14.3 (11.1 to 17.0) |
Time to tumor response (TTR) is defined as the time from date of enrollment to the date of first documented tumor response (CR or PR). PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Time to Tumor Response (TTR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (pEAS) | 1.9 (1.8 to 3.9) | 1.8 (1.1 to 2.0) | 1.0 (0.9 to 3.7) | 2.7 (1.0 to 5.6) |
Blood PK samples were collected either by direct venipuncture or an indwelling cannula inserted in a forearm vein for the determination of trough (Cmin) plasma concentrations of sonidegib and its main circulating metabolite, LGE899, from all patients who enrolled in the study. Blood was collected in Weeks 1, 3, 5, 9 (pre-dose), and subsequently pre-dose every 4 weeks up to Week 21, and every 12 weeks thereafter up to week 69.
| ng/mL | LDE225 200 mg qd | LDE225 800 mg qd |
|---|---|---|
| Week 1 (0 h (pre-dose)) | NA ± NA | NA ± NA |
| Week 3 (0 h (pre-dose)) | 207.76 ± 78.29 | 586.76 ± 97.13 |
| Week 5 (0 h (pre-dose)) | 372.26 ± 68.89 | 1012.63 ± 70.42 |
| Week 9 (0 h (pre-dose)) | 559.29 ± 67.30 | 1353.06 ± 63.43 |
| Week 13 (0 h (pre-dose)) | 714.01 ± 60.79 | 1443.84 ± 61.57 |
| Week 17 (0 h (pre-dose)) | 688.93 ± 64.43 | 1574.21 ± 59.88 |
| Week 17 (1 h (post-dose)) | 841.78 ± 52.57 | 1803.74 ± 39.47 |
| Week 17 (2 h (post-dose)) | 939.56 ± 50.79 | 1922.38 ± 34.90 |
| Week 17 (4 h (post-dose)) | 842.31 ± 62.22 | 1750.70 ± 53.32 |
| Week 17 (6 h (post-dose)) | 759.88 ± 63.43 | 1673.95 ± 41.53 |
| Week 21 (0 h (pre-dose)) | 707.49 ± 63.58 | 1547.41 ± 63.92 |
| Week 33 (0 h (pre-dose)) | 702.67 ± 93.11 | 1477.60 ± 74.80 |
| Week 45 (0 h (pre-dose)) | 697.92 ± 76.02 | 1368.87 ± 79.60 |
| Week 57 (0 h (pre-dose)) | 559.17 ± 117.27 | 1257.42 ± 78.96 |
| Wek 69 (0 h (pre-dose)) | 530.91 ± 154.33 | 1355.91 ± 89.03 |
OS is defined as the time from date of randomization to date of death due to any cause or the last date that a patient was known to be alive (censored observation) as of the data cut-off.
| Months | LDE225 200mg laBCC | LDE225 800mg laBCC | LDE225 200mg mBCC | LDE225 800mg mBCC |
|---|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | 47.6 (NA to NA) | 33.8 (NA to NA) |
Collected over Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 76.2 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LDE225 200 mg qd | 1/79 (1.3%) | 16/79 (20.3%) | 76/79 (96.2%) |
| LDE225 800 mg qd | 7/150 (4.7%) | 58/150 (38.7%) | 145/150 (96.7%) |
| Event | LDE225 200 mg qd | LDE225 800 mg qd |
|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 1/79 | 6/150 |
| AnaemiaBlood and lymphatic system disorders | 0/79 | 5/150 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/79 | 5/150 |
| VomitingGastrointestinal disorders | 0/79 | 4/150 |
| PneumoniaInfections and infestations | 2/79 | 3/150 |
| NauseaGastrointestinal disorders | 0/79 | 3/150 |
| DehydrationMetabolism and nutrition disorders | 1/79 | 3/150 |
| DiarrhoeaGastrointestinal disorders | 0/79 | 2/150 |
| Small intestinal obstructionGastrointestinal disorders | 0/79 | 2/150 |
| Abscess limbInfections and infestations | 0/79 | 2/150 |
| Event | LDE225 200 mg qd | LDE225 800 mg qd |
|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 43/79 | 104/150 |
| DysgeusiaNervous system disorders | 35/79 | 89/150 |
| AlopeciaSkin and subcutaneous tissue disorders | 39/79 | 87/150 |
| NauseaGastrointestinal disorders | 31/79 | 71/150 |
| Weight decreasedInvestigations | 24/79 | 64/150 |
| FatigueGeneral disorders | 26/79 | 55/150 |
| Blood creatine phosphokinase increasedInvestigations | 23/79 | 54/150 |
| Decreased appetiteMetabolism and nutrition disorders | 18/79 | 52/150 |
| DiarrhoeaGastrointestinal disorders | 25/79 | 34/150 |
| MyalgiaMusculoskeletal and connective tissue disorders | 15/79 | 42/150 |
The full analysis set (FAS) comprised all patients who were assigned study treatment irrespective of receiving it (all randomized patients). Patients were classified according to the treatment they were assigned in accordance with the intention-to-treat (ITT) principle.
| Age, Continuous(Years) | LDE225 (Sonidegib) 200 mg | LDE225 (Sonidegib) 800 mg | Total |
|---|---|---|---|
| Mean | 65.6 ± 15.67 | 63.6 ± 14.59 | 64.3 ± 14.96 |
| Sex: Female, Male(Participants) | LDE225 (Sonidegib) 200 mg | LDE225 (Sonidegib) 800 mg | Total |
|---|---|---|---|
| Female | 31 | 55 | 86 |
| Male | 48 | 96 | 144 |
| Race/Ethnicity, Customized(Participants) | LDE225 (Sonidegib) 200 mg | LDE225 (Sonidegib) 800 mg | Total |
|---|---|---|---|
| Black | 0 | 1 | 1 |
| Caucasian | 71 | 145 | 216 |
| Other | 8 | 5 | 13 |
Plan to share: Yes
Access criteria: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jun 2011 to primary completion in Jun 2013, 23 months.
Results were first posted in Nov 2015, 2 years 4 months after primary completion.
Of 43 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib